AbbVie Inc

AI Summary

AbbVie develops, manufactures, and sells prescription medicines across several core areas: immunology drugs for autoimmune diseases, oncology treatments for various cancers, neuroscience medications for conditions like migraine and Parkinson's disease, and aesthetic products including Botox and facial fillers [Company Overview]. The company also offers eye care products and treatments for hepatitis C and gastrointestinal conditions [Company Overview].

AbbVie is a major pharmaceutical company with $61.2 billion in annual revenue [Yahoo Finance], focused on treatments for autoimmune diseases (Skyrizi, Rinvoq), blood cancers (Imbruvica, Venclexta), and neurological conditions (Vraylar, Botox) [Company Overview]. The company generates strong cash flow ($17.8 billion free cash flow) and maintains a 70% gross margin [Yahoo Finance], though it carries significant debt (3.4x net debt to EBITDA) and trades at an extremely high valuation (105x earnings) [Yahoo Finance].

AbbVie is financially healthy with strong cash generation, though burdened by substantial debt and an elevated valuation.

Recent News

• Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum

  Yahoo Finance· 2026-05-20

• ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?

  Yahoo Finance· 2026-05-18

• Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

  Zacks· 2026-05-19

• Abbott Laboratories Insiders Added US$4.23m Of Stock To Their Holdings

  Yahoo Finance· 2026-05-19

• Kernicterus Market Research and Forecast Report 2026-2036 Featuring Pfizer, F.Hoffmann La Roche,. Merck, AbbVie, AsteraZeneca, Abbott Laboratories, Sanofi, GlaxoSmithKline, Grifols

  Yahoo Finance· 2026-05-18

• Polymyositis Market Research Report 2026-2036: Competitive Landscape is Dominated by Major Players Such As Teva Pharmaceuticals, Gilead Sciences, Roche, AbbVie, and Pfizer

  Yahoo Finance· 2026-05-19